Statistics for Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies
Total visits
| views | |
|---|---|
| Development and characterisation of neutralising mouse-human chimeric anti-SARS-CoV monoclonal antibodies | 202 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| Hay_Development_and.pdf | 364 |
Top country views
| views | |
|---|---|
| United States | 51 |
| Canada | 33 |
| Germany | 31 |
| China | 17 |
| Ireland | 11 |
| Finland | 5 |
| Sweden | 4 |
| Vietnam | 3 |
| France | 2 |
| United Kingdom | 2 |
| Cyprus | 1 |
| Hong Kong SAR China | 1 |
| Iran | 1 |
| Morocco | 1 |
| Malaysia | 1 |
| Peru | 1 |
| Singapore | 1 |
| Taiwan | 1 |
Top city views
| views | |
|---|---|
| Winnipeg | 32 |
| Ashburn | 22 |
| Dublin | 11 |
| Zhengzhou | 8 |
| Inglewood | 7 |
| Beijing | 3 |
| Hanoi | 3 |
| Helsinki | 3 |
| Brooklyn | 2 |
| Landshut | 2 |
| Los Angeles | 2 |
| Offenburg | 2 |
| Palo Alto | 2 |
| Stockholm | 2 |
| Union City | 2 |
| Boardman | 1 |
| Burton-on-Trent | 1 |
| Central | 1 |
| Des Moines | 1 |
| Frankfurt am Main | 1 |
| Hangzhou | 1 |
| Heidelberg | 1 |
| Lima | 1 |
| Mannheim | 1 |
| Morlenbach | 1 |
| Mountain View | 1 |
| Mudau | 1 |
| Nagold | 1 |
| Ningbo | 1 |
| Schwann | 1 |
| Seattle | 1 |
| Shah Alam | 1 |
| Singapore | 1 |
| Taichung | 1 |
| Tehran | 1 |